Vascular prostacyclin and plasminogen activator activity in experimental and clinical conditions of disturbed haemostasis or thrombosis

Research output: Contribution to journalArticlepeer-review

Abstract

In several experimental and clinical conditions associated with thrombotic tendency, or complicated by thrombotic episodes, either prostacyclin (which inhibits platelet aggregation) or plasminogen activator (which promotes fibrinolysis), or both, appear to be decreased in the vessel wall. In other conditions, however, either activity may not change or even be increased. Possibly, vascular damage is followed by an early stimulation of both activities (a defence mechanism?) which may be subsequently reduced or exhausted. While the role of vascular plasminogen activator in haemorrhagic conditions is apparently unknown, prostacyclin activity appears to be markedly enhanced both in experimental animals and in patients with uraemia and bleeding complications. There is a suggestive evidence that uraemic plasma powerfully stimulates vascular prostacyclin generation.

Original languageEnglish
Pages (from-to)300-311
Number of pages12
JournalPathophysiology of Haemostasis and Thrombosis
Volume8
Issue number3-5
DOIs
Publication statusPublished - 1979

Keywords

  • Haemostasis Thrombosis
  • Plasminogen activator
  • Prostacyclin

ASJC Scopus subject areas

  • Hematology
  • Physiology (medical)

Fingerprint Dive into the research topics of 'Vascular prostacyclin and plasminogen activator activity in experimental and clinical conditions of disturbed haemostasis or thrombosis'. Together they form a unique fingerprint.

Cite this